Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, reported its consolidated financial results for the quarter ending June 30, 2019. The company’s net profit jumped 37% in Q1FY20 to Rs124cr from Rs90cr in the same period previous fiscal.
For the quarter, EBITDA stood at Rs233cr, a growth of 54% yoy vs. Rs155cr over the corresponding quarter of the previous year.
Net sales were up 10% at Rs949cr in Q1 and Profit before exceptional items & tax up 58% to Rs192cr.
Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said "It was a good quarter for the company backed by exceptional growth in the US market. Our Oncology Manufacturing Facility was inspected by the USFDA with no observations."
For the quarter, EBITDA stood at Rs233cr, a growth of 54% yoy vs. Rs155cr over the corresponding quarter of the previous year.
Net sales were up 10% at Rs949cr in Q1 and Profit before exceptional items & tax up 58% to Rs192cr.
Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said "It was a good quarter for the company backed by exceptional growth in the US market. Our Oncology Manufacturing Facility was inspected by the USFDA with no observations."
No comments:
Post a Comment